Zaslat záznam emailem: Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukemia and non-Hodgkin’s lymphoma: Dose-limiting myelosuppression without evidence of DNA hypomethylation